scholarly journals Cardiometabolic Risk Factors in Rosuvastatin-Treated Men with Mixed Dyslipidemia and Early-Onset Androgenic Alopecia

Molecules ◽  
2021 ◽  
Vol 26 (10) ◽  
pp. 2844
Author(s):  
Robert Krysiak ◽  
Marcin Basiak ◽  
Bogusław Okopień
Keyword(s):  
Risk Factors ◽  
Uric Acid ◽  
Insulin Sensitivity ◽  
Early Onset ◽  
Cardiometabolic Risk ◽  
Androgenic Alopecia ◽  
Hydroxyvitamin D ◽  
Group A ◽  
25 Hydroxyvitamin D ◽  
Group B

Men with early-onset androgenetic alopecia are characterized by hormonal profiles similar to those observed in women with polycystic ovary syndrome. The purpose of this research was to investigate levels of cardiometabolic risk factors in 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)-treated men with early-onset androgenic alopecia. We studied two matched rosuvastatin-treated groups of men with mixed dyslipidemia: subjects with early-onset androgenic alopecia (group A) and subjects with normal hair growth (group B). Plasma lipids, glucose homeostasis markers, and levels of sex hormones, uric acid, hsCRP, homocysteine, fibrinogen, and 25-hydroxyvitamin D were measured before entering the study and six months later. Both groups differed in insulin sensitivity and levels of calculated bioavailable testosterone, dehydroepiandrosterone-sulfate, uric acid, hsCRP, fibrinogen, and 25-hydroxyvitamin D. Though observed in both study groups, treatment-induced reductions in total cholesterol, LDL cholesterol, hsCRP, and fibrinogen were more pronounced in group B than group A. Moreover, only in group A did rosuvastatin deteriorate insulin sensitivity, and only in group B did the drug affect uric acid, homocysteine, and 25-hydroxyvitamin D. The impact of rosuvastatin on cardiometabolic risk factors correlated with insulin sensitivity, calculated bioavailable testosterone, and dehydroepiandrosterone-sulfate. The obtained results suggest that men with early-onset androgenic alopecia may benefit to a lesser degree from rosuvastatin treatment than their peers.

scholarly journals Impaired metabolic effects of metformin in men with early-onset androgenic alopecia

2021 ◽  
Author(s):  
Robert Krysiak ◽  
Karolina Kowalcze ◽  
Bogusław Okopień
Keyword(s):  
Insulin Sensitivity ◽  
Early Onset ◽  
Plasma Lipids ◽  
Metabolic Effects ◽  
Metformin Treatment ◽  
Androgenic Alopecia ◽  
Hydroxyvitamin D ◽  
Group A ◽  
25 Hydroxyvitamin D ◽  
Group B

Abstract Background Early-onset androgenic alopecia is considered the phenotypic equivalent of polycystic ovary syndrome in men. The purpose of the current study was to investigate whether the presence of early-onset male-pattern baldness modulates metabolic effects of metformin. Methods This prospective case–control study included 2 groups of men at high risk for type 2 diabetes: 72 individuals with androgenic alopecia (group A) and 75 subjects with normal hair growth (group B). Both groups were matched for age, blood pressure, body mass index, insulin sensitivity and plasma lipids. Glycated hemoglobin, glucose, plasma lipids, indices of insulin sensitivity/resistance, sex hormones, high-sensitivity C-reactive protein (hsCRP) and 25-hydroxyvitamin D were determined before and after metformin treatment (1.7 g daily). Results Twelve-month metformin treatment reduced fat content, waist circumference, glycated hemoglobin, glucose and triglycerides, as well as improved insulin sensitivity. Although observed in both study populations, these effects were more pronounced in group B. Moreover, metformin decreased hsCRP and bioavailable testosterone levels in group B, as well as reduced 25-hydroxyvitamin D concentration in group A. Treatment-induced changes in glucose homeostasis markers correlated with the impact of metformin on hsCRP and 25-hydroxyvitamin D levels. Conclusions Metabolic effects of metformin in males are attenuated if they have coexisting early-onset androgenic alopecia. This finding may be partially explained by differences in severity of low-grade systemic inflammation and vitamin D status. The obtained results, requiring confirmation in large prospective studies, suggest that men with early-onset male-pattern baldness benefit to a lesser degree from metformin treatment than other men at high risk for type 2 diabetes.

Cardiometabolic Risk Factors in Men with Elevated Macroprolactin Content: A Pilot Study

2019 ◽  
Vol 129 (01) ◽  
pp. 7-13
Author(s):  
Robert Krysiak ◽  
Witold Szkróbka ◽  
Bogusław Okopień
Keyword(s):  
Uric Acid ◽  
Insulin Sensitivity ◽  
Plasma Levels ◽  
Cardiometabolic Risk ◽  
Plasma Lipids ◽  
Plasma Concentrations ◽  
Hdl Cholesterol ◽  
High Sensitivity ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D

Abstract Background Macroprolactinemia is a condition associated with the presence of large amounts of high molecular weight complexes of prolactin. Despite high prevalence, clinical significance of macroprolactin remains poorly understood. Objective The aim of this study was to assess cardiometabolic risk in men with isolated macroprolactinemia. Methods The study population included 11 men with isolated macroprolactinemia, 14 subjects with monomeric hyperprolactinemia and 14 men with prolactin levels within the reference range. Glucose homeostasis markers, plasma lipids, as well as plasma levels of uric acid, high-sensitivity C-reactive protein (hsCRP), fibrinogen, homocysteine and 25-hydroxyvitamin D were determined in all included patients. Results Compared to healthy counterparts, men with isolated macroprolactinemia had higher levels of 2-h postchallenge glucose, hsCRP and fibrinogen, lower levels of 25-hydroxyvitamin D and reduced insulin sensitivity. Patients with monomeric hyperprolactinemia were characterized by increased plasma levels of 2-h postchallenge glucose, triglycerides, uric acid, hsCRP, fibrinogen and homocysteine, reduced insulin sensitivity and decreased plasma concentrations of HDL cholesterol and 25-hydroxyvitamin D. Subjects with isolated macroprolactinemia differed from patients with monomeric hyperprolactinemia in postchallenge plasma glucose, insulin sensitivity, uric acid, hsCRP, fibrinogen, homocysteine and 25-hydroxyvitamin D. In men with monomeric hyperprolactinemia, uric acid, hsCRP, fibrinogen, homocysteine and 25-hydroxyvitamin D, while in men with elevated levels of macroprolactin, uric acid, hsCRP, fibrinogen and 25-hydroxyvitamin D correlated with a content of monomeric prolactin or macroprolactin, respectively, as well as with a degree of insulin sensitivity. Conclusions The obtained results suggest that macroprolactinemia may increase cardiometabolic risk but to a lesser extent than monomeric hyperprolactinemia.

scholarly journals The impact of exogenous vitamin D on thyroid autoimmunity in euthyroid men with autoimmune thyroiditis and early-onset androgenic alopecia

2021 ◽  
Author(s):  
Robert Krysiak ◽  
Karolina Kowalcze ◽  
Bogusław Okopień
Keyword(s):  
Vitamin D ◽  
Autoimmune Thyroiditis ◽  
Early Onset ◽  
Free Testosterone ◽  
Androgenic Alopecia ◽  
Hydroxyvitamin D ◽  
Antibody Titers ◽  
25 Hydroxyvitamin D ◽  
Group B ◽  
The Impact

Abstract Background Early-onset androgenic alopecia is regarded as the phenotypic equivalent of polycystic ovary syndrome in men. Women with polycystic ovary syndrome are at high risk of autoimmune thyroiditis. The aim of the current study was to investigate whether early-onset androgenic alopecia determines the impact of exogenous vitamin D on thyroid autoimmunity and thyroid function in men with autoimmune thyroiditis. Methods The study included 67 young men with autoimmune thyroiditis, 25 of whom had early-onset androgenic alopecia (group A). All 25 men with alopecia and 23 out of the 42 men with no evidence of hair loss, matched for age, antibody titers and thyrotropin levels (group B), were then treated with vitamin D (100 μg daily). Serum titers of thyroid peroxidase and thyroglobulin antibodies, serum levels of thyrotropin, free thyroid hormones, total and calculated free testosterone, dehydroepiandrosterone-sulfate, estradiol, prolactin and 25-hydroxyvitamin D, as well as the calculated parameters of thyroid homeostasis were assessed before vitamin D treatment and 6 months later. Results At baseline, thyroid antibody titers were higher in subjects with than without alopecia and correlated with calculated free testosterone levels. Vitamin D reduced antibody titers in both groups but this effect was stronger in group B than group A. Only in group B, vitamin D increased SPINA-GT. The impact of vitamin D on antibody titers correlated with 25-hydroxyvitamin D levels, calculated free testosterone, treatment-induced increase in 25-hydroxyvitamin D levels and the improvement in insulin sensitivity. Conclusion This study suggests that euthyroid men with early-onset androgenic alopecia may benefit to a lesser degree from vitamin D treatment than other subjects with autoimmune thyroiditis.

scholarly journals Serum 25-hydroxyvitamin D concentrations and cardiometabolic risk factors in adolescents and young adults

2016 ◽  
Vol 115 (11) ◽  
pp. 1994-2002 ◽  
Author(s):  
Lucinda J. Black ◽  
Sally Burrows ◽  
Robyn M. Lucas ◽  
Carina E. Marshall ◽  
Rae-Chi Huang ◽  
...  
Keyword(s):  
Risk Factors ◽  
Insulin Resistance ◽  
Vitamin D ◽  
Cardiometabolic Risk ◽  
Hdl Cholesterol ◽  
Cardiometabolic Risk Factors ◽  
Inverse Association ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D ◽  
Over Time

AbstractEvidence associating serum 25-hydroxyvitamin D (25(OH)D) concentrations and cardiometabolic risk factors is inconsistent and studies have largely been conducted in adult populations. We examined the prospective associations between serum 25(OH)D concentrations and cardiometabolic risk factors from adolescence to young adulthood in the West Australian Pregnancy Cohort (Raine) Study. Serum 25(OH)D concentrations, BMI, homoeostasis model assessment for insulin resistance (HOMA-IR), TAG, HDL-cholesterol and systolic blood pressure (SBP) were measured at the 17-year (n 1015) and 20-year (n 1117) follow-ups. Hierarchical linear mixed models with maximum likelihood estimation were used to investigate associations between serum 25(OH)D concentrations and cardiometabolic risk factors, accounting for potential confounders. In males and females, respectively, mean serum 25(OH)D concentrations were 73·6 (sd 28·2) and 75·4 (sd 25·9) nmol/l at 17 years and 70·0 (sd 24·2) and 74·3 (sd 26·2) nmol/l at 20 years. Deseasonalised serum 25(OH)D3 concentrations were inversely associated with BMI (coefficient −0·01; 95 % CI −0·03, −0·003; P=0·014). No change over time was detected in the association for males; for females, the inverse association was stronger at 20 years compared with 17 years. Serum 25(OH)D concentrations were inversely associated with log-HOMA-IR (coefficient −0·002; 95 % CI −0·003, −0·001; P<0·001) and positively associated with log-TAG in females (coefficient 0·002; 95 % CI 0·0008, 0·004; P=0·003). These associations did not vary over time. There were no significant associations between serum 25(OH)D concentrations and HDL-cholesterol or SBP. Clinical trials in those with insufficient vitamin D status may be warranted to determine any beneficial effect of vitamin D supplementation on insulin resistance, while monitoring for any deleterious effect on TAG.

Vitamin D Dosing Strategies Among Jordanians With Hypovitaminosis D

2016 ◽  
Vol 30 (2) ◽  
pp. 172-179 ◽  
Author(s):  
Nahla Khawaja ◽  
Mohammed Liswi ◽  
Mohammed El-Khateeb ◽  
Dana Hyassat ◽  
Dalila Bajawi ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Vitamin D ◽  
Hypovitaminosis D ◽  
Hydroxyvitamin D ◽  
Dosing Strategies ◽  
Optimal Maintenance ◽  
Group A ◽  
25 Hydroxyvitamin D ◽  
The Mean ◽  
Group B

Objective: To compare between weekly and daily cholecalciferol in patients with hypovitaminosis D and to determine the optimal maintenance dose. Methods: Seventy-one volunteers with hypovitaminosis D were randomly assigned to 2 dose regimens: cholecalciferol 50 000 IU weekly for 8 weeks, then 50 000 IU monthly for 2 months (group A) and 7000 IU daily for 8 weeks, then 12 500 IU weekly for 2 months (group B). Cholecalciferol was stopped for 2 months and reintroduced as 50 000 IU bimonthly for group A and 50 000 IU monthly for group B. Results: Two months after therapy, the mean serum 25-hydroxyvitamin D (25(OH)D) level increased from 11.4 to 51.2 ng/mL and from 11.7 to 44.9 ng/mL in groups A and B, respectively ( P = .065). The levels of 25(OH)D declined similarly in both groups during maintenance and after holding therapy. After resuming cholecalciferol, 25(OH)D levels increased to 33.8 and 28.8 ng/mL in groups A and B, respectively ( P = .027). There was a negative correlation between serum 25(OH)D levels and body mass index (BMI; P = .040). Conclusion: Timing and frequency of the dosing (daily vs weekly) have no effect on the rise in serum 25(OH)D levels as long as the accumulative dose of cholecalciferol is similar. Cholecalciferol 50 000 IU bimonthly is required to maintain sufficient 25(OH)D levels.

scholarly journals Healthy changes in some cardiometabolic risk factors accompany the higher summertime serum 25-hydroxyvitamin D concentrations in Iranian children: National Food and Nutrition Surveillance

2018 ◽  
Vol 21 (11) ◽  
pp. 2013-2021 ◽  
Author(s):  
Bahareh Nikooyeh ◽  
Zahra Abdollahi ◽  
Majid Hajifaraji ◽  
Hamid Alavi-Majd ◽  
Forouzan Salehi ◽  
...  
Keyword(s):  
Risk Factors ◽  
Vitamin D ◽  
Total Cholesterol ◽  
Cardiometabolic Risk ◽  
Linear Regression Analysis ◽  
Cardiometabolic Risk Factors ◽  
Healthy Children ◽  
Vitamin D Status ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D

AbstractObjectiveTo investigate seasonal variations of vitamin D status at different latitudes and if these changes are accompanied by corresponding variations in certain health parameters in children living in a broad latitudinal range in Iran.DesignLongitudinal study.SubjectsIn total, 530 apparently healthy children aged 5–18 years were randomly selected from six regions of Iran with a latitudinal gradient from 29°N to 37·5°N. All anthropometric and biochemical assessments were performed twice during a year (summer, winter). High BMI (Z-score >1), low HDL cholesterol (<40 mg/dl, males; <50 mg/dl, females) and high TAG (>150 mg/dl) were considered cardiometabolic risk factors.ResultsSerum 25-hydroxyvitamin D (25(OH)D) showed between-season variation, with significantly higher concentrations (mean (sd)) in summer v. winter (43 (29) v. 27 (18) nmol/l; P<0·001). Change of circulating 25(OH)D between summer and winter was negatively correlated with change of BMI (r=−0·16; P<0·001), TAG (r=−0·09; P=0·04) and total cholesterol (r=−0·10; P=0·02) and directly correlated with change of height-for-age Z-score (r=0·09; P=0·04). Multiple stepwise linear regression analysis (β; 95 % CI) showed that winter serum 25(OH)D (−0·3; −0·4, −0·2; P<0·001), gender (boys v. girls: 9·7; 5·2, 14·1; P<0·001) and latitude (>33°N v. <33°N: 4·5; 0·09, 9·0; P=0·04) were predictors of change of serum 25(OH)D between two seasons.ConclusionsSummertime improvement of vitamin D status was accompanied by certain improved cardiometabolic risk factors, notably serum TAG, total cholesterol and BMI, in children.

scholarly journals Rasprostranennost' ozhireniya,kardiometabolicheskikh faktorov riska,metabolicheskogo sindroma i sakharnogo diabetasredi zhenshchin razlichnykh vozrastnykh gruppMoskovskogo regiona

2009 ◽  
Vol 6 (4) ◽  
pp. 28-33
Author(s):  
S A Butrova ◽  
M A Berkovskaya ◽  
F Kh Dzgoeva ◽  
K A Komshilova
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Metabolic Syndrome ◽  
Cardiometabolic Risk ◽  
Age Groups ◽  
Visceral Obesity ◽  
Cardiometabolic Risk Factors ◽  
Group A ◽  
Group B ◽  
Parameters Measurement

The object of the study was to assess the frequency of visceral obesity, cardiometabolic risk factors, metabolic syndrome and diabetes mellitus in women of different ages. Materials and methods: 562 women from 20 to 65 years old were included and divided into 3 groups: 273 women < 45 years old (group A), 160 women of 45 - 55 years old (group B) and 129 - > 55 years old (group C). The examination included antropometric parameters, measurement of blood pressure, blood samples collection in order to investigate concentrations of glucose and lipids. Results: the frequency of visceral obesity was 52,0%, and metabolic syndrome - 18,1%. These frequencies increased in parallel with age. Higher insidence of arterial hypertension, hypercholesterolemia, hypertrigliceridemia and impaired fasting plasma gucose level were also observed with age. Diabetes mellitus was revealed in 1,2% of women. It`s frequency was 0,6% in group B and 4,7% in group C; in women younger than 45 years old no cases of diabetes mellitus were observed. Conclusion: significant increase of frequencies of visceral obesity, cardiometabolic risk factors, metabolic syndrome and diabetes mellitus in women older than 45, and especially - older than 55 years old stresses the necessity of an intense medical care for women of these age groups, and implementation of measures for prevention of cardiovascular diseases and diabetes mellitus.

Sign in / Sign up

Export Citation Format

Share Document